A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Active, not recruiting · Phase 3 · NCT02411448
Conditions: Metastatic Non-Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $7,025
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 545
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Ramucirumab (drug), Placebo (drug), Erlotinib (drug), Gefitinib (drug), Osimertinib (drug)
- Dates
- Started 2015-05-06; completion 2026-12
- Results posted
- Yes
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B. The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramuc…
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $7,025 in research payments for this study in 2025 (1 payments).
Products named: Cyramza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Hawaii $7,025
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.